Oestrone-targeted liposomes for mitoxantrone delivery via oestrogen receptor – synthesis, physicochemical characterization and <i>in-vitro</i> evaluation

Hao, Qiang; Yang, Yue; Sun, Yuxin; Cong, Dengli; Li, Hongrui; Liu, Xin; Wang, Zeng; Zhang, Zheng; Chen, Jing‐Lin; Li, Yao; Luan, Xue; Wang, Lin; Tian, Lin; Liu, Kun; Li, Yan; Jiao, Qianru; Pei, Jin

doi:10.1111/jphp.12736

Cited by 15 publications

(6 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Figure 6 shows that the molecular weight of the obtained SDSSD-DSPE is 3430.71, which means the distribution had its mode at 3430.71. The difference in molecular weight of SDSSD-DSPE between the theoretical mass and the experimental value obtained from Maldi-TOF is more likely due to the polydispersity of PEG2000 [ 39 ]. Additionally, the manufacturer’s certificate of analysis makes reference to it.…”

Section: Resultsmentioning

confidence: 99%

Peptide Engraftment on PEGylated Nanoliposomes for Bone Specific Delivery of PTH (1-34) in Osteoporosis

et al. 2023

View full text Add to dashboard Cite

Bone-specific functionalization strategies on liposomes are promising approaches to delivering the drug in osteoporotic conditions. This approach delivers the drug to the bone surface specifically, reduces the dose and off-target effects of the drug, and thereby reduces the toxicity of the drug. The purpose of the current research work was to fabricate the bone-specific peptide conjugated pegylated nanoliposomes to deliver anabolic drug and its physicochemical evaluations. For this, a bone-specific peptide (SDSSD) was synthesized, and the synthesized peptide was conjugated with a linker (DSPE-PEG2000-COOH) to obtain a bone-specific conjugate (SDSSD-DSPE). Purified SDSSD-DSPE was characterized by HPLC, Maldi-TOF, NMR, and Scanning Electron Microscope/Energy Dispersive Spectroscopy (SEM/EDS). Further, peptide-conjugated and anabolic drug-encapsulated liposomes (SDSSD-LPs) were developed using the ethanol injection method and optimized by Central Composite Design (CCD) using a statistical approach. Optimized SDSSD-LPs were evaluated for their physicochemical properties, including surface morphology, particle size, zeta potential, in vitro drug release, and bone mineral binding potential. The obtained results from these studies demonstrated that SDSSD-DSPE conjugate and SDSSD-LPs were optimized successfully. The particle size, % EE, and zeta potential of SDSSD-LPs were observed to be 183.07 ± 0.85 nm, 66.72 ± 4.22%, and −25.03 ± 0.21 mV, respectively. SDSSD-LPs demonstrated a sustained drug release profile. Further, the in vitro bone mineral binding assay demonstrated that SDSSD-LPs deliver the drug to the bone surface specifically. These results suggested that SDSSD-LPs could be a potential targeting approach to deliver the anabolic drug in osteoporotic conditions.

show abstract

Section: Resultsmentioning

confidence: 99%

Peptide Engraftment on PEGylated Nanoliposomes for Bone Specific Delivery of PTH (1-34) in Osteoporosis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…ES-PEG 2000 -DSPE was synthesized by our laboratory as described previously [ 34 ]. Gemcitabine hydrochloride was purchased from Meilun Biotechnology (Dalian, China).…”

Section: Methodsmentioning

confidence: 99%

Efficient Delivery of Gemcitabine by Estrogen Receptor-Targeted PEGylated Liposome and Its Anti-Lung Cancer Activity In Vivo and In Vitro

et al. 2023

Self Cite

View full text Add to dashboard Cite

Lung cancer is one of the main causes of cancer-related deaths. At present, the main treatment method for lung cancer is chemotherapy. Gemcitabine (GEM) is widely applied in lung cancer treatment, but its lack of targeting ability and serious side effects limit its application. In recent years, nanocarriers have become the focus of research to solve the above problems. Here, we prepared estrone (ES)-modified GEM-loaded PEGylated liposomes (ES-SSL-GEM) for enhanced delivery by identifying the overexpressed estrogen receptor (ER) on lung cancer A549 cells. We studied the characterization, stability, release behavior, cytotoxicity, targeting ability, endocytosis mechanism, and antitumor ability to prove the therapeutic effect of ES-SSL-GEM. The results showed that ES-SSL-GEM presented a uniform particle size of 131.20 ± 0.62 nm, a good stability, and a slowly released behavior. Moreover, ES-SSL-GEM enhanced tumor-targeting ability, and the endocytosis mechanism studies confirmed that the ER-mediated endocytosis had the most crucial effect. Furthermore, ES-SSL-GEM had the best inhibitory effect on A549 cell proliferation and significantly suppressed the tumor growth in vivo. These results suggest that ES-SSL-GEM is a promising agent for treating lung cancer.

show abstract

“…After being fully dissolved, the rotary evaporator slowly vacuumed to remove the chloroform to form a dry lipid film, then 5% glucose solution with a CBP concentration of 2.0 mg/mL was added to hydrate the dry lipid film at 37°C for 1 h, followed by vortex oscillation. The DSPE-PEG 2000 -ES solution (lipids: DSPE-PEG 2000 -ES = 200:1 molar ratio) prepared as described previously 53 was incubated with the above liposome for 1 h at 37°C in a water bath. The liposomes were sonicated through the probe for 10 min.…”

Section: Methodsmentioning

confidence: 99%

Estrone-Conjugated PEGylated Liposome Co-Loaded Paclitaxel and Carboplatin Improve Anti-Tumor Efficacy in Ovarian Cancer and Reduce Acute Toxicity of Chemo-Drugs

Tang

Xie

Zhu

et al. 2022

IJN

View full text Add to dashboard Cite

Oestrone-targeted liposomes for mitoxantrone delivery via oestrogen receptor – synthesis, physicochemical characterization and in-vitro evaluation

Abstract: Our results provide a proof of principle that ES-modified PEGylated liposomes can target the ER, thereby potentially improving the therapeutic benefits in ER-overexpressed tumours.

Cited by 15 publications

References 48 publications

Peptide Engraftment on PEGylated Nanoliposomes for Bone Specific Delivery of PTH (1-34) in Osteoporosis

Peptide Engraftment on PEGylated Nanoliposomes for Bone Specific Delivery of PTH (1-34) in Osteoporosis

Efficient Delivery of Gemcitabine by Estrogen Receptor-Targeted PEGylated Liposome and Its Anti-Lung Cancer Activity In Vivo and In Vitro

Estrone-Conjugated PEGylated Liposome Co-Loaded Paclitaxel and Carboplatin Improve Anti-Tumor Efficacy in Ovarian Cancer and Reduce Acute Toxicity of Chemo-Drugs

Contact Info

Product

Resources

About